(RTTNews) - Amgen Inc. (AMGN) reported earnings for its third quarter that increased from the same period last year and beat the Street estimates. The company's bottom line came in at $2.83 ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Amgen Inc.'s Q3 earnings — due 30th October -are unlikely to be a major upside catalyst due to tricky comparisons, increased R&D spending, and transitional phase challenges. Key patents expiring ...

THOUSAND OAKS, Calif., Oct. 25, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the fourth quarter of 2024. The ...

Today, a brief rundown of news from GSK and Amgen, as well as updates from Roche, AbbVie, and Marinus Pharmaceuticals that you may have missed. GSK is making its largest investment in U.S.

If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. At the same time ...

Are you a print subscriber? Activate your account. By Mikey Garcia - 41 min 54 sec ago By Adrianne Pasquarelli - 1 hour 4 min ago By Ad Age and Creativity Staff - 1 hour 13 min ago By Brandon ...

Thousand Oaks, CA-based biotechnology company Amgen has selected IPG Mediabrands to handle its U.S. media agency assignments after a formal review that began earlier this year. Incumbents included ...

Oct 22 (Reuters) - Amgen (AMGN.O), opens new tab will launch its biosimilar version of Regeneron's (REGN.O), opens new tab blockbuster eye care drug Eylea following a U.S. appeals court ruling in ...

Regeneron Pharmaceuticals Inc. failed to block Amgen Inc.'s biosimilar of Eylea while it appeals a West Virginia federal judge’s denial of Regeneron’s request for a preliminary injunction, though the ...